WCLC 2020 Faculty Chairs Disclosure Summary

Total Page:16

File Type:pdf, Size:1020Kb

WCLC 2020 Faculty Chairs Disclosure Summary WCLC 2020 Faculty Chairs Disclosure Summary Name of Individual Individual's Name of Commercial Interest(s) Nature of Relationship(s) Adusumilli, Prasad FacultyRole(s) in Activity 1) ATARA Biotherapeutics (Patents, royalties and intellectual 1) Royalty/Intellectual property/Patent property on mesothelin-targeted CAR and other T-cell holder therapies) 2) Contracted/Support research grant 2) ATARA Biotherapeutics 3) Consultant 3) ATARA Biotherapeutics Aerts, Joachim Chair 1) MSD, BMS, Roche, Astra-Zeneca, BAyer, Eli-Lilly, Boehringer 1) Advisory Board Ingelheim, Takeda, Amphera, BIOCAD 2) Ownership or Stock interest 2) Amphera 3) Royalty/Intellectual property/Patent 3) allogenic tumor cell lysate/JAK inhibition in holder immunooncology/ biomarker for immuno-oncology (all institution) Aggarwal, Charu Faculty 1) BMS, ROCHE, AZ, MERCK, Celgene, BluePrint, Diachaii Sankyo 1) Advisory Board 2)Allogenic tumor cell lysate/JAK inhibition in immuno- 2) Royalties/Intellectual Property/Patent oncology/biomarker for immuno-oncology (all institution) Holder to institution 3) AZ, Merck, Xencor, Novartis 3) Research grants to institution Agrawal, Abhinav Faculty Nothing to disclose Nothing to disclose Ahn, Myung-Ju Faculty 1) AstraZeneca, MSD, Lilly, Bristol-Myers Squibb, Takeda, 1) Advisory Board Amgen, Roche, Merck, Pfizer 2) Consultant 2) Alpha Pharmaceutical, Yuhan, Progenere Aisner, Dara Faculty Nothing to disclose Akerley, Wallace Faculty Nothing to disclose Nothing to disclose Akhtar-Danesh, Gilly Faculty Nothing to disclose Nothing to disclose Ambrogio, Chiara Faculty 1) Revolution Medicines 1) Contracted/Support reseach grant Andarini, Sita Chair 1) Astra Zeneca, Boehringer Ingelheim, MSD, Kalbe Innolab, 1) Speakers Bureau Pfizer, Roche, Takeda 2) Advisory Board 2) Astra Zeneca, Boehringer Ingelheim, MSD, Roche 3) Contracted/Support research grant 3) Astra Zeneca, Boehringer Ingelheim Antonoff, Mara Faculty Nothing to disclose Nothing to disclose Arenberg, Douglas Faculty Nothing to disclose Nothing to disclose Arrato, Nicole Faculty Nothing to disclose Nothing to disclose Arriola Aperribay, Edurne Faculty 1) Roche, Merck, BMS, AstraZeneca, Lilly, Pfizer, Boehringer, 1) Speakers Bureau Takeda 2) Speakers Bureau 2) Travel/ Accomodation: Roche, Merck, BMS, AstraZeneca, Lilly, Pfizer, Boehringer Asamura, Hisao Faculty 1) Johnson and Johnson, Covidien, Taiho, Astelllas, Lily 1) Contracted/Support research grant 2) Foudation Medicine, Roche 2)Consultant 3) Eisai 3) Advisory Board Awad, Mark Faculty 1) Merck, Achilles, Abbvie, AstraZeneca, Bristol-Myers Squibb 1) Consultant 2) AstraZeneca, Genentech, Bristol-Myers Squibb, Eli Lilly and 2) Contracted/Support research grant Company Azar, Ibrahim Faculty Nothing to disclose Nothing to disclose Bai, Xue Faculty Nothing to disclose Nothing to disclose Bakitas, Marie Faculty Nothing to disclose Nothing to disclose Balata, Haval Faculty Nothing to disclose Nothing to disclose Baldwin, David Faculty 1) Honoraria from AZ, MSD, Bristol Myers Squibb and Roche for 1) AdvisoryBoard lectures / webinars / advisory groups Bastani, Mehrad Faculty Nothing to disclose Nothing to disclose Beattie, Vanessa Chair Nothing to disclose Nothing to disclose Belderbos , Robert Faculty Nothing to disclose Nothing to disclose 1/21 WCLC 2020 Faculty Chairs Disclosure Summary Name of Individual Individual's Name of Commercial Interest(s) Nature of Relationship(s) Besse, Benjamin FacultyRole(s) in Activity 1) Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, 1) Contracted/Support research grant BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma. Investigator or co- investigator of trials: Nerviano, GSK, Pfizer, Roche-Genentech, Lilly, OSE Pharma, MSD, Celgene, Stemcentrx, Ignyta, Abbvie, Loxo Oncology, AstraZeneca, Blueprint Medicines. Best, Sarah Faculty Nothing to disclose Nothing to disclose Bezjak, Andrea Faculty 1) Astra Zeneca 1) Speakers Bureau Bi, Nan Faculty Nothing to disclose Nothing to disclose Blackhall, Fiona Chair 1) Astra Zeneca, Takeda 1) Speakers Bureau 2) AZ Cellgene Roche Amgen 2) Consultant 3) AZ Roche Amgen 3) Contracted/Support research grant Boni, Valentina Faculty Nothing to disclose Nothing to disclose Borghaei, Hossein Chair 1) Genentech, Celgene, Pfizer, Merck, Astra Zeneca, Novartis, 1) Advisory Board Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, Axiom, 2) Ownership or Stock Interest SonnetBio (scientific advisory Board), RGenix (Scientific 3) Honorarium received from promotional Advisory Board) activities 2) SonnetBio, Rgenix 4) Contracted/Support Research Grant 3) Lilly, Pfizer, Daiichi 4) BMS/Lilly, Merck/Celgene, Millennium Borondy-Kitts, Andrea Faculty 1) Johnson & Johnson, Abbvie, Abbott Labs, 1) Ownership or Stock interest 2) Astra Zeneca, Prosumer Health - - a start-up company 2) Other developing an AI driven individualized mobile health platform to help individuals manage their health and healthcare Bosch-Barrera, Joaquim Faculty Nothing to disclose Nothing to disclose Boyer, Michael Faculty 1) Bristol-Myers Squibb, Astra Zeneca, and Janssen 1) Advisory Borad 2) Merck Sharpe and Dohme, Bristol-Myers Squibb, Astra 2) Contracted/Support research grant Zeneca, Amgen, Roche, Pfizer, and Janssen 3) Consultant 3) Cancer Aid Brahmer, Julie Faculty 1) Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, 1) Advisory Board Merck, GlaxoSmithKline, Sanofi 2) Consultant 2) Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, 3) Honorarium received from promotional Merck, GlaxoSmithKline, Sanofi activities 3) Genentech 4) Contracted/Support research grant 4) Bristol Myers Squibb 5) Other - Travel Accomodation Expenses & 5) Travel / Accommodation Expenses: Genentech Data & Safety Safety Monitoring Board/Committees Monitoring Board/Committees: GlaxoSmithKline, Sanofi Brastianos, Priscilla Faculty 1) Angiochem, Merck, Genentech-Roche, Lilly, Tesaro, 1) Consultant ElevateBio,Pfizer (Array), Dantari 2) Contracted/Support research grant 2) Merck, BMS, Lilly 3) Honorarium received from promotional 3) Merck, Genentech-Roche, Lilly, Pfizer activities 2/21 WCLC 2020 Faculty Chairs Disclosure Summary Name of Individual Individual's Name of Commercial Interest(s) Nature of Relationship(s) Bubendorf, Lukas FacultyRole(s) in Activity 1) Boehringer Ingelheim, Astra Zeneca , Eli Lilly, Bayer 1) Advisory Board 2) Roche, Novartis 2) Ownership or Stock interest 3) Bayer 3) Honorarium received from promotional 4) Roche activities 4) Contracted/ Support research grant Burgess, Lisa Faculty Nothing to disclose Nothing to disclose Califano, Raffaele Faculty 1) MSD 1) Institutional Grant Support Calles, Antonio Chair 1) Merck Sharp & Dohme 1) Advisory Board Carbone, David Chair 1) MSD, EMD Serono, AZ, GSK, DSI 1) Advisory Board 2) Pfizer, AZ, GenePlus, BMS, Inivata, GSK 2) Speakers Bureau Carbone, Michele Faculty Nothing to disclose Nothing to disclose Casali, Paolo Faculty Nothing to disclose Nothing to disclose Cedzynska, Magdalena Faculty Nothing to disclose Nothing to disclose Chai, Hui Zhong Faculty Nothing to disclose Nothing to disclose Chan, Alexandre Faculty Nothing to disclose Nothing to disclose Chan, Joyce Faculty Nothing to disclose Nothing to disclose Chang, Yeun-Chung Faculty Nothing to disclose Nothing to disclose Chaoqiang, Deng Faculty Nothing to disclose Nothing to disclose Charalambous, Andreas Faculty Nothing to disclose Nothing to disclose Chen, Haiquan Faculty Nothing to disclose Nothing to disclose Chen, Jing-Hua Faculty Nothing to disclose Nothing to disclose Chen, Wanqing Faculty Nothing to disclose Nothing to disclose Chen, Xiaoyuan Faculty Nothing to disclose Nothing to disclose Cheung, Yin Bun Faculty Nothing to disclose Nothing to disclose Chiang, Anne Faculty 1) AbbVie, Boehringer Ingelheim, AstraZeneca, Genentech, BMS 1) Advisory Board 2) AstraZeneca 2) Consultant 3) AstraZeneca, BMS, Merck, Amgen , Abbvie 3) Contracted/Support research grant Ching, Shirley Siu-yin Faculty Nothing to disclose Nothing to disclose Chino, Fumiko Faculty 1) Memorial Sloan Kettering Cancer Center 1) Employment 2) NYU Langone Health - Bellevue Hospital 2) Employment -Spouse Cho, Byoung Chul Faculty 1) Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, 1) Advisory Board Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, 2) Honorarium received from promotional Abbvie, Medpacto, GIInnovation, Eli Lilly, Blueprint medicines, activities Interpark Bio Convergence Corp 3) Contracted/Support research grant 2) DAAN Biotherapeutics 4) Ownership or Stock interest 3) TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, 5) Board of Directors KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp 4) KANAPH Therapeutic Inc, Brigebio therapeutics, Cyrus therapeutics, Guardant Health 5) Gencurix Inc, Interpark Bio Convergence Corp Chou, Teh-Ying Chair 1) Roche 1) Speakers Bureau, Advisory Board, Consultant Chua, Alfredo Faculty Nothing to disclose Nothing to disclose Chua, Kevin Faculty 1) Astrazeneca 1) Advisory Board 2) National Cancer Centre Singapore 2) Employment Ciupek, Andrew Faculty Nothing to disclose Nothing to disclose 3/21 WCLC 2020 Faculty Chairs Disclosure Summary Name of Individual Individual's Name of Commercial Interest(s) Nature of Relationship(s) Coate, Linda FacultyRole(s) in Activity 1) abbvie 1) Contracted/Support research grant 2) pfizer 2) Speakers/Bureau 3) astellas, astrazeneca, roche, MSD 3) Advisory Board Cooke, Saskia Faculty Nothing to disclose
Recommended publications
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • Mirati's Clinical Programs
    NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation August 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, are "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1955, that involve significant risks and uncertainties. Forward looking statements can be identified by the use of forward looking words such as “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” “pro forma,” or “anticipates,” or other similar words (including their use in the negative), or by discussions of future matters such as the development of current or future product candidates, timing of potential development activities and milestones, business plans and strategies, possible changes in legislation and other statements that are not historical. Forward-looking statements are based on current expectations of management and on what management believes to be reasonable assumptions based on information currently available to them, and are subject to risks and uncertainties. Such risks and uncertainties may cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation potential delays in development timelines, negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks detailed in Mirati's recent filings on Forms 10-K and 10-Q with the U.S. Securities and Exchange Commission. Except as required by law, Mirati undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
    [Show full text]
  • Introducing the IMED Biotech Unit What Science Can Do Introduction What Science Can Do
    Introducing the IMED Biotech Unit What science can do Introduction What science can do At AstraZeneca, our purpose is to push the Our IMED Biotech Unit applies its research and Our approach to R&D development capabilities and technologies to The IMED Biotech Unit plays a critical boundaries of science to deliver life-changing accelerate the progress of our pipeline. Through role in driving AstraZeneca’s success. Working together with MedImmune, medicines. We achieve this by placing science great collaboration across our three science units, our global biologics arm and Global we are confident that we can deliver the next wave Medicines Development (GMD), our at the centre of everything we do. late-stage development organisation, of innovative medicines to transform the lives of we are ensuring we deliver an innovative patients around the world. and sustainable pipeline. Pancreatic beta cells at different Eosinophil prior to Minute pieces of circulating tumour DNA stages of regeneration apoptosis (ctDNA) in the bloodstream IMED Biotech Unit MedImmune Global Medicines Development Focuses on driving scientific advances Focuses on biologics research and Focuses on late-stage development in small molecules, oligonucleotides and development in therapeutic proteins, of our innovative pipeline, transforming other emerging platforms to push the monoclonal antibodies and other next- exciting science into valued new boundaries of medical science. generation molecules to attack a range medicines and ensuring patients of diseases. around the world can access them. It’s science that compels us to push the boundaries of what is possible. We trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease.
    [Show full text]
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • 2020-2021 Cancer Communications Committee Disclosures All Relationships Are Considered Compensated
    2020-2021 Cancer Communications Committee Disclosures All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Name EMAIL Committee Employment Leadership Stock and Other Honoraria Consulting or Advisory Speakers' Bureau Research Funding Patents, Royalties, Other Expert Testimony Travel, Other Relationship (OPTIONAL) (OPTIONAL) Open Member Status Ownership Interests Role Intellectual Property Accommodations, Uncompensated Payments Link Expenses Relationships Neeraj Agarwal [email protected] Active Astellas Pharma Active Biotech (Inst) Astellas Pharma Amgen (Inst) AstraZeneca AstraZeneca (Inst) AstraZeneca Bavarian Nordic (Inst) AVEO Bayer (Inst) Bayer BN ImmunoTherapeutics Bristol-Myers Squibb (Inst) Calithera Biosciences Bristol-Myers Squibb (Inst) Eisai Calithera Biosciences EMD Serono (Inst) Exelixis Celldex (Inst) Foundation Medicine Eisai (Inst) Foundation One Inc Exelixis (Inst) Genentech Genentech (Inst) Janssen Oncology GlaxoSmithKline (Inst) Lilly Immunomedics (Inst) Lilly Janssen (Inst) lily Merck (Inst) Medivation/Astellas Newlink Genetics (Inst) MEI Pharma Novartis (Inst) Merck Pfizer (Inst) Nektar Prometheus (Inst) Novartis Rexahn Pharmaceuticals Pfizer (Inst) Pfizer Sanofi (Inst) Pharmacyclics Takeda (Inst) Seattle Genetics TRACON Pharma (Inst) Muhammad S. Beg muhammad.beg@utsouthwestern. Active Array BioPharma Agios (Inst) edu AstraZeneca/MedImmune ArQule (Inst) Cancer Commons AstraZeneca/MedImmune Ipsen (Inst) Legend Biotech
    [Show full text]
  • Spectrum Pharmaceuticals Inc
    SPECTRUM PHARMACEUTICALS INC FORM 10-K (Annual Report) Filed 03/12/14 for the Period Ending 12/31/13 Address 11500 S. EASTERN AVE., SUITE 240 HENDERSON, NV 89052 Telephone 702-835-6300 CIK 0000831547 Symbol SPPI SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2014, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 93 -0979187 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 11500 South Eastern Avenue, Suite 240 Henderson, Nevada 89052 (Address of principal executive offices) (702) 835-6300 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $0.001 par value The NASDAQ Stock Market, LLC Rights to Purchase Series B Junior Participating Preferred Stock Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Based on Our Discussion with Radford, Management Identified Our Peer Companies to Include the Following 19 Biotechnology and Pharmaceutical Companies for 2015
    Based on our discussion with Radford, management identified our peer companies to include the following 19 biotechnology and pharmaceutical companies for 2015: Ariad Pharmaceuticals Inc. Infinity Pharmaceuticals, Inc. Progenics Pharmaceuticals, Inc. Array BiopPharma, Inc. Lexicon Pharmaceuticals, Inc Repligen Corporation Celldex Therapeutics, Inc. MacroGenics, Inc. Spectrum Pharmaceuticals, Inc. CTI BioPharma Corp. Merrimack Pharmaceuticals, Inc. Synta Pharmaceuticals Corp. DepoMed Inc. NewLink Genetics Corporation XOMA Corporation Halozyme Therpeutics, Inc. OncoMed Pharmaceuticals, Inc. Immunomedics Inc. Peregrine Pharmaceuticals, Inc These peer companies were selected from among publicly-held U.S. pharmaceutical and biotechnology companies with comparable operations in mid– to late–stages of product development or small commercial products in the U.S. based on the following criteria: number and stage of development programs; number of employees; market capitalization; and number of and revenue from commercial products. The market data included information as to base salaries, cash bonuses and stock option awards. Use of Compensation Consultants Our Compensation Committee is authorized to retain its own independent advisors to assist in carrying out its responsibilities. Our Compensation Committee engaged Radford to analyze historic compensation and establish recommendations for executive compensation for 2015 and methodologies for determining compensation on an on-going basis. Benchmarking in the Context of Our Other Executive Compensation Principles Our Compensation Committee and our Board of Directors use market data as one means of evaluating and establishing executive pay. In instances where an executive officer is believed to be especially suited to our company or important to our success, the Compensation Committee may establish or recommend compensation that deviates from industry averages or other specific benchmarks.
    [Show full text]
  • Beigene, Ltd. 百濟神州有限公司 (Incorporated in the Cayman Islands with Limited Liability) (Stock Code: 06160)
    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. BeiGene, Ltd. 百濟神州有限公司 (incorporated in the Cayman Islands with limited liability) (Stock Code: 06160) INSIDE INFORMATION CHINA NMPA APPROVES BRUKINSA® (ZANUBRUTINIB) FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTRÖM’S MACROGLOBULINEMIA This announcement is issued pursuant to Rule 13.09 of the Rules Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited and under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On June 18, 2021 (U.S. Eastern Time), BeiGene, Ltd. (“BeiGene” or the “Company”) announced that BRUKINSA® (zanubrutinib) has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy. The supplemental new drug application was previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA in October 2020. Attached hereto as Schedule 1 is the full text of the press release issued by the Company on June 18, 2021 (U.S. Eastern Time) announcing the above-described business updates. 1 Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential clinical benefits and advantages of BRUKINSA compared to other BTK inhibitors; BeiGene’s plans for the advancement, and anticipated clinical development, regulatory milestones and commercialization of BRUKINSA; and BeiGene’s plans, commitments, aspirations, and goals under the headings “BeiGene Oncology” and “About BeiGene”.
    [Show full text]
  • JMP Securities Healthcare Conference to Be Held in New York
    JMP Securities Healthcare Conference to Be Held in New York SAN FRANCISCO, Oct 01, 2008 (BUSINESS WIRE) -- JMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that its broker-dealer subsidiary, JMPSecurities, will host the third annual JMP Securities Healthcare Focus Conference at Le Parker Meridien in New York on Monday and Tuesday, October 6 and 7, 2008. The two-day conference will feature presentations by senior executives of nearly 90 public and private companies in the biotechnology, medical devices and healthcare services industries before an audience of institutional investors and financial sponsors. For additional details or to register to attend the event, visit www.jmpsecurities.com/about/events.html or www.twstevent.com/jmp.html. Companies scheduled to present as of September 30, 2008; subject to change: A.D.A.M., Inc. ACADIA Pharmaceuticals Inc. Acceleron Pharma, Inc. Achillion Pharmaceuticals, Inc. Alexza Pharmaceuticals, Inc. Allos Therapeutics, Inc. Allscripts Healthcare Solutions, Inc. Alnylam Pharmaceuticals, Inc. American CareSource Holdings, Inc. Anadys Pharmaceuticals, Inc. ARCA biopharma, Inc. Ardea Biosciences, Inc. athenahealth Inc. AtriCure, Inc. AVEO Pharmaceuticals, Inc. AVI BioPharma, Inc. BioCryst Pharmaceuticals, Inc. C. R. Bard, Inc. Cadence Pharmaceuticals, Inc. Celera Corporation Celgene Corporation Celleration, Inc. Cerus Corporation Chem Rx Corporation Concert Pharmaceuticals, Inc. Corcept Therapeutics Incorporated Cypress Bioscience, Inc. Cytokinetics, Incorporated DexCom, Inc. DiagnoCure Inc. Dialysis Corporation of America Echo Therapeutics, Inc. Eclipsys Corp. Enanta Pharmaceuticals, Inc. Endocare Inc. Exelixis, Inc. EyeGate Pharmaceuticals, Inc. Genomic Health, Inc. Given Imaging, Ltd. HeartWare Limited Horizon Therapeutics, Inc. Human Genome Sciences, Inc. HydroCision, Inc. Idenix Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.
    [Show full text]
  • Company Description
    November 8, 2017 Laura S. Engel, CPA [email protected] 214-987-4121 MARKET STATISTICS COMPANY DESCRIPTION Exchange / Symbol NasdaqGS: SPPI Spectrum Pharmaceuticals, Inc. is focused on the acquisition, development and Price: $19.00 commercialization of proprietary drugs, primarily addressing the oncology/hematology Market Cap ($mm): $1,912.6 markets. Spectrum's business strategy involves in-licensing or acquiring diversified drugs Enterprise Value ($mm): $1,766.6 as well as creating an expanding pipeline of prospective candidates in late-stage Phase 2 and Phase 3 clinical trials. Over the years, the Company has developed comprehensive in- Shares Outstanding (mm): 100.7 house clinical development/regulatory capabilities, along with an extensive commercial Float: 85% network, including a direct sales force in the U.S. and distributors in Europe and Japan Volume (3-month avg., mm): 1.8 for its marketed products. Spectrum’s diverse portfolio consists of six marketed oncology drugs and a pipeline with three advanced stage products that address sizable markets. 52-week Range: $3.73 – $21.95 Spectrum Pharmaceuticals is headquartered in Henderson, Nevada, and as last reported, Industry: Biotechnology the Company had 227 employees. CONDENSED BALANCE SHEET ($mm, except per share data) Balance Sheet Date 9/30/2017 SUMMARY Cash & Cash Equivalents: $247.7 Over the last several quarters, Spectrum’s primary focus has shifted beyond its Cash/Share: $2.46 established portfolio of niche cancer drugs to opportunities for its newer drugs, with three in its late-stage pipeline (Poziotinib, Rolontis™, and Qapzola®), and all of which Debt: $101.8 have meaningful competitive advantages and address indications with significant Equity (Book Value): $304.7 populations.
    [Show full text]
  • Astrazeneca Plc
    6/15/2020 AstraZeneca - Wikipedia AstraZeneca AstraZeneca plc[3] is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its global AstraZeneca plc headquarters in Cambridge, England.[4] Its R&D is concentrated in Cambridge, Gaithersburg, Maryland, and Mölndal in Sweden.[5] AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, Type Public limited neuroscience, respiratory and inflammation.[6] company Traded as LSE: AZN (https:// The company was founded in 1999 through the merger of the www.londonstocke [7][8] Swedish Astra AB and the British Zeneca Group (itself formed xchange.com/exch by the demerger of the pharmaceutical operations of Imperial ange/searchengin Chemical Industries in 1993). Since the merger it has been among e/search.html?lang the world's largest pharmaceutical companies and has made =en&x=0&y=0&q= numerous corporate acquisitions, including Cambridge Antibody AZN) Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) NYSE: AZN (http and Definiens (by MedImmune in 2014). s://www.nyse.com/ quote/XNYS:AZN) AstraZeneca has a primary listing on the London Stock Exchange Nasdaq and is a constituent of the FTSE 100 Index. It has secondary listings Stockholm: AZN (ht on the New York Stock Exchange and the OMX exchange. tp://www.nasdaqom xnordic.com/aktier/ microsite?language Contents Id=1&Instrument=S SE3524) History FTSE 100 2000–06 Component 2007–12: The patent cliff and subsequent acquisitions ISIN GB0009895292 2013
    [Show full text]
  • Pharmaceuticals in the Environment
    Pharmaceuticals in the Environment As a responsible healthcare company, we are committed to the health and safety of our society and planet. We make it a priority to effectively manage the risks associated with pharmaceuticals in the environment (PIE). 1 How do Pharmaceutical Products get into the Environment? Pharmaceuticals enter the environmental mainly as AstraZeneca supports actions based on scientific a result of patient use, where they can pass through evidence to address the challenges presented by PIE. our bodies and into waterways. Drug manufacture and These include: the improper disposal of unused medicines also add • Assessing the environmental risk of our medicines to the trace levels of pharmaceuticals in rivers, lakes, to support drug marketing authorisations soils, and, sometimes, drinking water. AstraZeneca recognises that, even in such low concentrations, • Actively managing the environmental risks resulting the risks associated with Pharmaceuticals in the from our manufacturing Environment (PIE) should be determined, minimised • Supporting industry and government efforts to and managed. improve medicine disposal programs and education • Co-sponsoring research to fill scientific gaps 88% to understand and mitigate the risks of PIE. as a result of patient use To learn more about the risks associated with PIE and what we are doing to manage them please click here. 2% attributed to waste Pharmaceuticals from production in the environment 10% from unused medicines that people don’t dispose of properly 2 Societal Concerns about PIE Trace amounts of pharmaceuticals have been detected in the environment for more than 20 years. As environmental monitoring expands and the methods for measuring pharmaceuticals in the environment become more sophisticated and detection limits get better, the geographical scope and number of pharmaceuticals measured in the environment will grow.
    [Show full text]